Comparative efficacy and safety of Chinese herbal injections combined with transcatheter hepatic arterial chemoembolization in treatment of liver cancer: a bayesian network Meta-analysis

作     者：Zhang Dan Wang Kaihuan Zheng Jiewen Wu Jiarui Duan Xiaojiao Ni Mengwei Liu Shuyu Zhang Bing Zhao Yi Zhang Dan;Wang Kaihuan;Zheng Jiewen;Wu Jiarui;Duan Xiaojiao;Ni Mengwei;Liu Shuyu;Zhang Bing;Zhao Yi

作者机构：Department of Clinical Pharmacology of Traditional Chinese MedicineSchool of Chinese Materia MedicaBeijing University of Chinese MedicineBeijing 100102China 

出 版 物：《Journal of Traditional Chinese Medicine》 (中医杂志（英文版）)

年 卷 期：2020年第40卷第2期

页      面：167-187页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(Study on the Key Influential Factors of Anaphylaxis Induced by Chinese Herbal Injection Based on Three-dimensional Database and Multi-dimensional Data Mining,No.81473547 Establishment of Multi-dimensional Clinical Evaluation Model of Danshen Injection for Treating Unstable Angina Pectoris Based on Bayesian Network Meta Analysis,No.81673829) 

主　　题：Liver neoplasms Chemoembolization,therapeutic Drugs,Chinese herbal Injections Network Meta-analysis 

摘      要：OBJECTIVE: To address the optimal Chinese herbal injections(CHIs) against liver cancer, the present network Meta-analysis is designed to investigate the comparative efficacy and safety of different ***: Several electronic databases were searched up to June 1 st, 2017. The quality assessment was conducted and network Meta-analysis was performed to compare the efficacy and safety of different CHIs plus transcatheter hepatic arterial chemoembolization(TACE). Primary outcomes were 1-year and 2-year survival rate, the secondary outcomes includes the clinical effective rate, performance status and the adverse reactions(ADRs). Data analysis was applied Stata 13.0 and Win BUGS 1.4 ***: A total of 105 randomized controlled trials(RCTs) were identified for inclusion in this analysis, with data for 7683 patients and 13 CHIs. The results suggested that Javanica oil emulsion,Huachansu injection plus TACE were more favorable for 1-year and 2-year survival rate than other CHIs. Kanglaite, Astragalus polysaccharide injection plus TACE showed superiority in the clinical effective rate and performance status over other *** Shenmai injection plus TACE was superior to reducing ADRs than other CHIs for patients with liver ***: Our findings indicated that receiving CHIs combined with TACE may have therapeutic benefits for patients with liver cancer in improving survival rate, clinical effective rate, the performance status and alleviating the ADRs.